Favorable safety and tolerability, particularly when compared to standard of care biologics or JAKs Max response rates have not yet been observed; strict continuation criteria at three months in this ...

GSK has claimed a new approval for its respiratory syncytial virus (RSV) vaccine Arexvy, currently locked in a battle for market share with rival shots from Pfizer and Moderna, that could lend it ...

The FDA has started a review of MSD's respiratory syncytial virus (RSV) antibody clesrovimab, with a verdict due in the middle of next year. If approved by the 10th June action date, clesrovimab ...

The infection commonly referred to as RSV has started losing its hold in other parts of the country, and Dr. Theresa Cullen — the county’s health director — said Wednesday during a news ...

E. histolytica specifically upregulate KERP1 on its surface during pathogenesis of amoebic liver abscess. A E. histolytica Gal-lectin based, simple noninvasive immunization strategy has been ...